Denali Therapeutics (DNLI) Receivables - Net (2018 - 2026)
Denali Therapeutics (DNLI) reported Receivables - Net of $1.6 million for Q1 2026, down 5.88% year-over-year from $1.7 million in Q1 2025, and little changed on a QoQ basis from $1.6 million in Q4 2025.
Denali Therapeutics (DNLI) has 8 years of Receivables - Net data on file, last reported at $1.6 million in Q1 2026.
- Quarterly Receivables - Net fell 5.88% year-over-year to $1.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.6 million (down 5.88% YoY) and the FY2025 annual result came in at $2.2 million, up 45.13% from the prior year.
- Receivables - Net held at $1.6 million in Q1 2026 per DNLI's latest filing, from $1.6 million in the prior quarter.
- Across five years, Receivables - Net topped out at $3.4 million in Q4 2023 and bottomed at $1.4 million in Q2 2024.
- The 4-year median for Receivables - Net is $1.7 million (2025), against an average of $2.0 million.
- The widest annual swing landed in 2024, when Receivables - Net tumbled 58.82%; it then surged 35.71% in 2025.
- Tracing DNLI's Receivables - Net over 4 years: stood at $3.4 million in 2023, then slumped by 56.14% to $1.5 million in 2024, then increased by 6.67% to $1.6 million in 2025, then changed by 0.0% to $1.6 million in 2026.
- Per Business Quant, the three latest DNLI Receivables - Net figures stand at $1.6 million (Q1 2026), $1.6 million (Q4 2025), and $1.9 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Denali Therapeutics | 3.82 Bn | 3.82 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.60 Mn |
| Mar 31, 2026 | 1.60 Mn |
| Dec 31, 2025 | 1.60 Mn |
| Dec 31, 2025 | 1.60 Mn |
| Sep 30, 2025 | 1.90 Mn |
| Sep 30, 2025 | 1.90 Mn |
| Jun 30, 2025 | 1.40 Mn |
| Jun 30, 2025 | 1.40 Mn |
| Mar 31, 2025 | 1.70 Mn |
| Mar 31, 2025 | 1.70 Mn |
| Dec 31, 2024 | 1.50 Mn |
| Dec 31, 2024 | 1.50 Mn |
| Sep 30, 2024 | 1.40 Mn |
| Sep 30, 2024 | 1.40 Mn |
| Jun 30, 2024 | 1.40 Mn |
| Jun 30, 2024 | 1.40 Mn |
| Mar 31, 2024 | 1.90 Mn |
| Mar 31, 2024 | 1.90 Mn |
| Dec 31, 2023 | 3.42 Mn |
| Dec 31, 2023 | 3.42 Mn |
| Sep 30, 2023 | 2.10 Mn |
| Sep 30, 2023 | 2.10 Mn |
| Jun 30, 2023 | 3.40 Mn |
| Jun 30, 2023 | 3.40 Mn |
| Mar 31, 2023 | 3.20 Mn |
| Mar 31, 2023 | 3.20 Mn |
| Jun 30, 2021 | 15.22 Mn |
| Jun 30, 2021 | 15.22 Mn |
| Dec 31, 2020 | 44,303.00 |
| Dec 31, 2020 | 44,303.00 |
| Sep 30, 2020 | 100,000.00 |
| Sep 30, 2020 | 100,000.00 |
| Jun 30, 2020 | 300,000.00 |
| Jun 30, 2020 | 300,000.00 |
| Mar 31, 2020 | 500,000.00 |
| Mar 31, 2020 | 500,000.00 |
| Dec 31, 2019 | 1.20 Mn |
| Dec 31, 2019 | 1.20 Mn |
| Sep 30, 2019 | 2.40 Mn |
| Sep 30, 2019 | 2.40 Mn |
| Jun 30, 2019 | 3.40 Mn |
| Jun 30, 2019 | 3.40 Mn |
| Mar 31, 2019 | 3.40 Mn |
| Mar 31, 2019 | 3.40 Mn |
| Dec 31, 2018 | 2.30 Mn |
| Dec 31, 2018 | 2.30 Mn |